


3.2.1 Extramural funding for Research (Grants sponsored by the non-government sources such as industry, corporate houses, international bodies for research projects) endowments, Chairs in the University during the year (INR in Lakhs)

Name of the Scheme/Project/ Endowments/ Chairs	Name of the Principal Investigator/ Co Investigator (if applicable)	Name of the Funding agency	Type (Government/Non-Government)	Department	Year of Award	Funds provided (INR in lakhs)	Duration of the project
Beyond Standard Model Physics with Neutrino and Dark Matter at Energy, Intensity and Cosmic Frontiers	Dr. Manimala Mitra	CENTRE FRANCO-INDIEN POUR LA PROMOTION DE LA RECHERCHE A VANCEE	Non-Government	Physical Sciences	2021-22	8.29	3 years
Intermediate fellowship of India Alliance DBT wellcome	Dr.Mohammed Saleem	India Alliance DBT Wellcome	Non-Government	Life Science	2021-2022	93.65	5 years
Stipend for Project Fellow	Dr.Satyaprasad Premswarup Senanayak	The Peridot Technologies	Non-Government	Physical Sciences	2021-2022	1.44	1 year
Chanakya Doctoral Fellowship	Dr.Ashok Mohapatra	I-HUB QUANTUM TECHNOLOGY FOUNDATION	Non-Government	Physical Sciences	2021-2022	3.92	4 years
Research Fund grant (R21-7309528179)	Dr. P C Ravikumar	Royal Society of Chemistry	Non-Government	Chemical Sciences	2021-2022	3.91	1 year
TIRTHA	Dr.Subhankar Mishra	Dassault Systemes Foundation	Non-Government	Mathematical Sciences	2021-2022	28.50	1.5 years
Chanakya Post-Doctoral Fellow	Dr. Sanker De	I-HUB:CHAN	Non-Government	I-HUB QTF	2022-2024	12.60	2 years
EMC3-Eirene simulations of main chamber recycling on ITER	Dr. Devendra Sharma	ITER International Fusion Energy Organization	Non-government	Physical Sciences	2021	16.75	1 year 4 months
Feasibility study on surface activation of polystyrene using low pressure plasma	Dr. Ramkrishna Rane	Accumax Lab Devices Private Limited	Non-government	Physical Sciences	2021	6.00	1 year
A Phase III Trial Evaluating The Role Of Ovarian Function Suppression And The Role Of Exemestane As Adjuvant Therapies For Premenopausal Women With Endocrine Responsive Breast Cancer (SOFT Trial)	Dr. Vani Parmar	ETOP INTERNATIONAL BREST CANCER STUDY GROUP	Non-Government	Medical and Health science	2005	40.09	18 Years
A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer (TEXT Trial)	Dr. Vani Parmar	ETOP IBCSG	Non-Government	Medical and Health science	2005	27.19	18 Years
Inter laboratory comparison program for immunophenotyping by flow cytometry	Dr. Sumeet Gujral	TMC-Corporate Research fund	Non-Government	Medical and Health science	2006	14.88	years 5 Months 18 Days
ALTO-EGF106708- A randomized, multi-center, open-label, phase III study of adjuvant Lapatinib, Trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer	Dr. Sudeep Gupta	NOVARTIS	Non-Government	Medical and Health science	2008	63.09	15 Years


 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR

Compilation of data as received from Dean-Academic
 of the various CI's/OCC of HBNI

होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशाक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Development of a cohort study to identify and evaluate transitions in lifestyle and risk factors in a rural population with a low cancer disease risk at baseline.	Dr. Rajesh Dikshit	World Cancer Research Fund (WCRF), Center for Global Health Research (CGHR), International Agency for Research on cancer (IARC)	Non-Government	Medical and Health science	2008	119.97	13 Years
Effectiveness and safety of 2 versus 3 doses of HPV Vaccine in preventing cervical cancer: An Indian multi-centre randomized trial	Dr. Sharmila Pimple	International Agency for Research on Cancer, World Health Organization, Lyon, France	Non-Government	Medical and Health science	2010	177.37	18 Years
Establishment of registry for Epidemiology and end result - analysis in lymphoma (REEA-L) and Establishment of lymphoma tumor tissue repository at the Tata Memorial Hospital (LTTR)	Dr. Navin Khattry	DR. REDDY'S LAB	Non-Government	Medical and Health science	2010	55.00	Years 9 Months 19 Days
A randomized trial to evaluate the efficacy and safety of Pemetrexed and Platinum Vs Gefitinib in Non-Small Cell Lung Cancer patients	Dr. Kumar Prabhash	TMH + NATCO Non-Government	Non-Government	Medical and Health science	2010	15.44	12 Years
Effect of COX-2 and EGFR suppression on markers of angiogenesis and proliferation in squamous cell carcinoma of oral cavity a prospective randomized study.	Dr. Sudhir Vasudevan Nair	Intramural + SERB	Non-Government	Medical and Health science	2011	40.53	12 Years
An Open label, Randomized, Investigator Initiated Multicentric, Phase III Study of Nimotuzumab in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subjects with Locally advanced Squamous Cell Carcinoma of the Head and Neck (LASCCHN)	Dr. Kumar Prabhash	BIOCON	Non-Government	Medical and Health science	2011	82.14	12 Years
Asia CML Registry (ACR): Web based registry	Dr. Navin Khattry	ASIAN GOVERNMENT RESERACH FUND	Non-Government	Medical and Health science	2011	2.77	13 Years
Protocol No. - D4200000000 : Study Code D4200C00088-A Randomized, International, Open-Label, Multi-Centre, Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer Experience Grade 2 or Higher Adverse Events during the First 12 Months of Treatment with Vandetanib	Dr. Vanita Noronha	SANOFI HEALTHCARE INDIA PRIVATE LIMITED (SHIPL)	Non-Government	Medical and Health science	2011	15.40	12 Years

Compilation of data as received from Dean-Academic of various CT's/OCC of HBNI

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुशलिक / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Phase III Study Evaluating Efficacy and Safety of low dose Gemcitabine compared to standard dose Gemcitabine with platinum in advanced non-small cell lung cancer	Dr. Kumar Prabhash	ICON	Non-Government	Medical and Health science	2012	26.12	10 Years
Establishment of audit for collating the data of lung cancer patients receiving systemic therapy with palliative intent in India.	Dr. Vanita Noronha	ICON	Non-Government	Medical and Health science	2012	3.60	11 Years
A Randomized controlled study to evaluate the role of hydroxy-progesterone in prevention of chemotherapy induced neurotoxicity in women with breast cancer	Dr. Rajendra Badwe	ICON	Non-Government	Medical and Health science	2013	80.19	10 Years
Protocol No. EMR 062202 559- A prospective, open label, multicentric data collection registry in order to describe treatment choices in management of metastatic colorectal cancer (mCRC) patients with unresectable hepatic and / or extra hepatic disease, across treatment lines (Asian Metastatic Colorectal Cancer Registry)	Dr. Shailesh Shrikhande	Merck PVT Ltd.	Non-Government	Medical and Health science	2013	8.90	9 Years
Breast Cancer Registry to collate data on epidemiology and treatment patterns & outcomes of breast cancer in India	Dr. Sudeep Gupta	BIOQUEST SOLUTIONS PVT LTD	Non-Government	Medical and Health science	2014	2.87	6 Years 7 Months
Protocol No. CABAZL06500- A phase II controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel in recurrent head and neck cancer in India	Dr. Kumar Prabhash	SANOFI	Non-Government	Medical and Health science	2015	71.75	8 Years
A collaborative, multicentre, national trial for newly diagnosed patients with acute lymphoblastic leukaemia (ICICLE-2014)	Dr. Gaurav Narula	Intramural seed & ICMR /NCG	Non-Government	Medical and Health science	2014	42.46	9 Years
Protocol No. CLDK378A2301-A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer.	Dr. Sabita Jiwnani	NOVARTIS HEALTHCARE	Non-Government	Medical and Health science	2014	39.22	7 Years 2 Months
Genomic Profiling in Thyroid Carcinoma	Dr. Anuradha Chougule	ICON	Non-Government	Medical and Health science	2015	92.44	3 Years 6 Months
Retrospective and anonymized study on breast tumors for identification of markers predictive of risk of recurrence.	Dr. Sudeep Gupta	OncoStem Diagnostics, Bangalore	Non-Government	Medical and Health science	2014	14.66	7 Years 9 Days

Compilation of data as received from various
CT's / occ of HBNI.

Dr. P. S. Solvin / Registrar
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशाक्ती नगर, मुंबई - ४०० ०९ ४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

A Phase III randomized clinical trial to study the radiosensitizing effect of Nelfinavir in Advanced Carcinoma of Cervix. (NELCER Trial)	Dr. Supriya Chopra	TMH+ VARIAN GRANT RESEARCH	Non-Government	Medical and Health science	2017	225.96	8 Years
Prospective observational cohort study of advanced Gall bladder cancer patients to study the impact of clinical and molecular characteristics and outcome	Dr. Vikas Ostwal	MERCK PVT LTD	Non-Government	Medical and Health science	2015	39.66	7 Years
Protocol No. RI-02-003- Reditux TM Registry to compare Effectiveness, Safety and Resource Utilization of Reditux vs. the Reference Medicinal Product to treat Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia in Routine Clinical Practice	Dr. Manju Sengar	DR.REDDYS LAB/Phamax Analytic Resources Pvt Ltd	Non-Government	Medical and Health science	2016	32.64	7 Years
Scalp Cooling for the prevention of chemotherapy induced alopecia in breast cancer from a tertiary care cancer center in India	Dr. Jyoti Bajpai	Access Devices	Non-Government	Medical and Health science	2016	15.00	8 Years
Metronomic Adjuvant Chemotherapy Evaluation in locally advanced oral cancers post surgery and appropriate adjuvant therapy	Dr. Pankaj Chaturvedi	TMC-Corporate Research fund	Non-Government	Medical and Health science	2016	69.06	8 Years
Image Texture Analysis in assessing tumour heterogeneity: A tool to predict, prognosticate cancers and individualize radiotherapy.	Dr. Jai Prakash Agarwal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2016	97.67	7 Years
A phase III, double blind, Placebo controlled, randomized trial assessing the effect of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumor. (Add Aspirin Study)	Dr. C. S. Pramesh	TATA TRUST	Non-Government	Medical and Health science	2016	1560.33	10 Years
Pregnancy Associated Cancer (PAC) Registry to collate data on epidemiology and treatment patterns & outcomes."	Dr. Jyoti Bajpai	Roche Pvt. Ltd	Non-Government	Medical and Health science	2017	6.16	6 Years
A prospective observational study to determine the risk of Hepatitis B viral reactivation in adolescent and adult acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) with Occult Hepatitis B infection (OHBI).	Dr. Hasmukh Jain	TMC+ UNRESTRICTED EDUCATIONAL GRANT	Non-Government	Medical and Health science	2016	2.51	8 Years
Randomized study of stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) in hepatocellular carcinoma (IAEA study)	Dr. Supriya Chopra	IAEA	Non-Government	Medical and Health science	2016	9.40	6 Years

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin

6 Years

Compilation of data as received from Dean Academic, Homi Bhabha National Institute, Mumbai

कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Evaluation of VEGF expression of tumor cells as a potential prognostic marker in Ewing's sarcoma	Dr. Jyoti Bajpai	Roche Products India Pvt. Ltd	Non-Government	Medical and Health science	2016	62.37	7 Years
Protocol No. - I3Y-CR-JPBQ : A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSA1 plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or plus Placebo and to Compare Fulvestrant plus Abemaciclib or plus Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Loco regionally Recurrent or Metastatic Breast Cancer	Dr. Jyoti Bajpai	Eli Lilly and Company India Pvt. Ltd	Non-Government	Medical and Health science	2016	116.30	6 Years
Intensity modulated radiotherapy with IGRT for Post cricoid and upper esophageal cancer: prospective observational study	Dr. Sarbani Ghosh Laskar	IMRT-IGRT/ Rapidarc Inc Ltd (Madison, WI, USA)	Non-Government	Medical and Health science	2017	93.16	6 Years 6 Months
A Situation Analysis of National Radiotherapy Resources and Patterns of Care for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes	Dr. Sarbani Ghosh Laskar	IAEA	Non-Government	Medical and Health science	2017	10.53	6 Years
Satisfaction in Patients on Outpatient Radiation Therapy (SPORT study)	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical and Health science	2017	.10	6 Years 3 Months
DHANUSH : Docetaxel as radiosensitizer in Head And Neck cancer patients, Unsuitable for cisPlatin based cHemoradiation	Dr. Vijay Patil	ICON	Non-Government	Medical and Health science	2017	59.21	12 Years
A two arm randomized open label prospective parallel design superiority Phase II multicentric clinical trial to evaluate the efficacy of a doublet second line chemotherapy versus monotherapy in advanced unresectable or metastatic gall bladder cancer progressing on first line chemotherapy (GB-SELECT)	Dr. Anant Ramaswamy	TERRY FOX	Non-Government	Medical and Health science	2017	61.70	6 Years 6 Months
Profiling the incidence of ROS1 alteration discovered in human Non Small Cell Lung Cancer	Dr. Kumar Prabhash	TMH+PFIZER PVT LTD	Non-Government	Medical and Health science	2017	27.57	3 Years
Protocol No. - 000201 : An Open-label, Single-arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® (Degarelix) in Androgen Deprivation Therapy in Indian Patients Diagnosed with Advanced Hormone-dependent Prostate Cancer.	Dr. Mahendra Pal	FERRING Non-Government CEUTICAL PVT LTD	Non-Government	Medical and Health science	2017	11.09	3 Years 8 Months

Compilation of data as received from Dean-Academic of various ^{कुलसचिव / REGISTRAR} ~~होमि भाभा राष्ट्रीय संस्थान~~ ^{होमि भाभा राष्ट्रीय संस्थान}

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvi

HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

A randomized trial to compare gefitinib plus chemotherapy vs chemotherapy alone in EGFR positive and T790M mutation negative advanced Non-small cell lung cancer patients after progression on first line gefitinib.	Dr. Amit Joshi	ICON -Indian cooperative Oncology Network	Non-Government	Medical and Health science	2018	31.80	5 Years
Protocol No. - GBR 200-301 : A Prospective, Multicenter, Randomized, Double-blind, Parallel group Study to Compare the Efficacy and Safety of GBR 200 (similar biologic of Trastuzumab) versus Innovator Trastuzumab both when Given in Combination with Paclitaxel in Patients Diagnosed with HER2 Positive Metastatic Breast Cancer	Dr. Shalaka Joshi	ALKEM LABORATORIES LTD	Non-Government	Medical and Health science	2017	57.36	5 Years 6 Months
A clinical trial to test the number of circulating tumor cells (CTCs) captured by the OncoDiscover Liquid Biopsy Technology in peripheral blood samples of Head and Neck cancer patients.	Dr. Pankaj Chaturvedi	ACTORIUS INNOVATIONS AND RESEARCH PVT LTD.	Non-Government	Medical and Health science	2017	3.40	5 Years 6 Months
Quality Assurance (QA) Program for Molecular Diagnostic testing in Solid Tumors	Dr. Omshree Shetty	NATIONAL CANCER GRID	Non-Government	Medical and Health science	2017	111.06	5 Years
"Advancing Cancer-care through CANScript™ Enabled Personalized Treatment (ACCEPT): A non-randomized, investigator initiated, observational trial to measure predictive power of CANScript™ for chemotherapeutics and targeted therapy in patients with newly diagnosed, locally advanced head & neck cancer and refractory / relapsed triple negative breast cancer"	Dr. Shripad Banavali	Mitra Biotech Pvt. Ltd, Bangalore	Non-Government	Medical and Health science	2018	201.69	5 Years
Phase IIb/III, Placebo-controlled, double-blind randomized clinical trial, using Curcumin and Metformin in patients with previous history of head and neck squamous cell carcinoma, in an attempt to lower the incidence of second primary tumor	Dr. Sudhir Vasudevan Nair	NATIONAL CANCER GRID	Non-Government	Medical and Health science	2018	30.79	6 Years
CONcurrent versus SEquential Chemo-Endocrine therapy in ER positive and HER2 negative non-metastatic breast cancer (CONSEQUENCE)	Dr. Shalaka Joshi	CSR Fund from Gen. Insu. Co.	Non-Government	Medical and Health science	2018	194.40	10 Years

पो पी सी सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

पो पी सी सेल्विन / Prof. P. C. Selvin

कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean - Academic

Protocol No. - MO29872 : A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab compared with Chemotherapy in Patients with Treatment-Naïve Advanced or Recurrent (Stage IIIB not amenable for multimodality treatment) or Metastatic(Stage IV) Non-Small Cell Lung Cancer who are deemed unsuitable for Platinum-Containing therapy	Dr. Kumar Prabhash	Roche Products (India) Pvt. Ltd	Non-Government	Medical and Health science	2017	199.11	5 Years 4 Months
Protocol No. - MO39196 : A Phase III, Multicentre, randomised, double-blind, placebo controlled study of Atezolizumab (anti-PD-L1 antibody) in combination with paclitaxel compared with placebo in combination with paclitaxel for patients with previously untreated, inoperable locally advanced or metastatic Triple Negative Breast Cancer.	Dr. Sudeep Gupta	Roche Products (India) Pvt. Ltd	Non-Government	Medical and Health science	2018	130.33	4 Years
Use of PET-CT with Gallium-68 labelled prostate Specific Membrane Antigen in the Diagnosis and Follow-up of patients with Prostate Cancer	Dr. Archi Agrawal	IAEA	Non-Government	Medical and Health science	2018	13.58	4 Years 6 Months
Utility of MRI in detecting peritoneal metastases in gastric cancer patients with negative CECT abdomen	Dr. Akshay Baheti	CIPLA	Non-Government	Medical and Health science	2018	6.80	6 Years
Protocol No. - I3Y-MC-JPCF : A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer (MonarchE)	Dr. Seema Gulia	Eli Lilly and Company India Pvt. Ltd.	Non-Government	Medical and Health science	2018	217.30	10 Years
Prevalence of MMR status in gallbladder cancer (GBC) treated with palliative intent and its correlation with response to chemotherapy and survival.	Dr. Vikas Ostwal	Cadila healthcare limited	Non-Government	Medical and Health science	2018	17.45	5 Years
Introduction of a novel, cost effective, multigene panel for NSCLC patients - A pilot project	Dr. Rajiv Kumar	TMH-Corporate Research fund	Non-Government	Medical and Health science	2018	206.86	5 Years
Multi-Centric Clinical Trials of Indigenous TKP 2.4: Implant and Pilot Production of TKP 2.4	Dr. Ashish Gulia	Non-ferrous Materials Technology Development Centre, Hyderabad	Non-Government	Medical and Health science	2019	427.90	5 Years

Compilation of data as received from Dean-Academic of various *REH* *संस्थान / REGISTRAR* *होमि भाभा राष्ट्रीय संस्थान*
 Dr. P. S. Salvi / Prof. P. U. Servedi
 HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - WO40242 : A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of Atezolizumab (Anti-Pd-L1 Antibody) As Adjuvant Therapy After Definitive Local Therapy In Patients With High-Risk Locally Advanced Squamous Cell Carcinoma Of The Head And Neck	Dr. Kumar Prabhash	Roche Products (India)	Non-Government	Medical and Health science	2018	141.74	7 Years
Protocol No. - SII-qHPV/IN-02 : A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the Immunogenicity and Safety of SIIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers According to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil®)	Dr. Sharmila Pimple	Serum Institute of India Pvt. Ltd, Hadapsar, Pune (Sponsor)	Non-Government	Medical and Health science	2018	137.25	4 Years 9 Months
Prevalence of Gallstone diseases in the regions with the high and low incidence of gallbladder cancer: current status and future perspective for gallbladder cancer prevention	Dr. Sharayu Mhatre	TMC-TMC-Corporate Research fund	Non-Government	Medical and Health science	2018	69.78	4 Years
Protocol No. - 19214 : A phase IV study to investigate the safety and efficacy of regorafenib in Indian patients with metastatic colorectal cancer (mCRC)	Dr. Vikas Ostwal	Bayer AG, D-51368 Leverkusen, Germany	Non-Government	Medical and Health science	2018	87.49	5 Years
Docetaxel or Cisplatin radiosensitizer in Head and Neck cancer patients for curative or adjuvant chemoradiation	Dr. Kumar Prabhash	Oncology Care Associates, ICON Trust	Non-Government	Medical and Health science	2018	30.84	6 Years
Sequential Abiraterone following Docetaxel Chemotherapy in Hormone Sensitive Metastatic Prostate Cancer	Dr. Amit Joshi	TMC-TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	1362.90	10 Years
Protocol No. - ECTS/16/002 : A multicentric open label phase II safety and efficacy study of ormeloxifene in tamoxifen resistant metastatic/recurrent breast cancer patients.	Dr. Sudeep Gupta	HLL Lifecare Limited	Non-Government	Medical and Health science	2018	49.70	4 Years
Carboplatin/paclitaxel versus cisplatin/5-fluorouracil definitive chemoradiotherapy for locoregionally advanced unresectable esophageal and gastroesophageal junction cancer.	Dr. Nandini Menon	TMC-Corporate Research fund	Non-Government	Medical and Health science	2018	33.72	10 Years

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin

REGISTRAR
 ज्योति बाबा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुसक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean-Academic of Various CI/OC of MSBSI

Protocol No. - 0063-17 : A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy.	Dr. Sudeep Gupta	Intas Non-Governmentceuticals Ltd., Corporate Office Bldg., Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India	Non-Government	Medical and Health science	2018	244.65	4 Years
A pilot evaluation of prognostic molecular and serum biomarkers of disease recurrence after chemoradiation in patients with locally advanced cervical cancer from EMBRACE study group (BIO-EMBRACE-1)	Dr. Supriya Chopra	BIOEMBRACE RESEARCH GROUP	Non-Government	Medical and Health science	2019	23.60	4 Years
Two arm, triple blinded, randomized placebo controlled, prospective, parallel design Phase II integrated phase III study to evaluate the role of Carica papaya leaf extract (CPLE) in reducing the duration of chemotherapy induced thrombocytopenia and adverse events related to thrombocytopenia	Dr. Vikas Ostwal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	41.59	4 Years 6 Months
A phase-3 randomized control trial comparing hydroxyurea and L-asparaginase for cytorreduction in pediatric AML patients presenting with hyperleukocytosis	Dr. Shripad Banavali	SOHN FOUNDATION THROUGH GRAVIS	Non-Government	Medical and Health science	2018	23.59	4 Years
Validation of the Beta Defensin Index (BDI) as a Biomarker for Oral Cancer - India	Dr. Deepa Nair	Case Western University, cleaveland	Non-Government	Medical and Health science	2018	9.02	4 Years 6 Months
A prospective evaluation of a point of care saliva-based detection test based on soluble CD44 (OncAlert) for the presence of disease in a previously untreated oral cavity and oropharynx squamous cell carcinoma.	Dr. Sudhir Vasudevan Nair	Tata Trusts, Vigilant Biosciences	Non-Government	Medical and Health science	2018	17.06	4 Years
Protocol No. - CACZ885T2301 : A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIa and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)	Dr. Vijay Patil	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical and Health science	2019	89.05	7 Years

Compilation of data received from Dean-Academic of various

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 HOD / REGISTRAR
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०१२
 Training School Complex, Anushakti Nagar, Mumbai - 400 014

A Pilot study to evaluate tracer uptake characteristics in high grade neoplastic brain lesions on Ga-68 PSMA PET/CT imaging	Dr. Ameya Puranik	TMC-Corporate Research fund	Non-Government	Medical and Health science	2018	13.81	4 Years
Human cancer pathology atlas (HCPA) & Machine learning and Artificial intelligence in Pathology (MAP)	Dr. Swapnil Rane	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	1474.33	5 Years
Early detection programme for Oral, Breast and Cervical Cancer in Sangrur district of Punjab State	Dr. Atul Budukh	Local donar has donated the funds for early detection programme	Non-Government	Medical and Health science	2019	171.29	4 Years 6 Months
A two arm randomized open label Phase II clinical trial to assess the efficacy of Gemcitabine-cisplatin or Capecitabine and Concurrent chemoradiation in Operated stage II & III GB cancer (GECCOR-GB)	Dr. Anant Ramaswamy	Zybus Non-Governmentceuticals, Dr. Reddy's Laboratories Limited	Non-Government	Medical and Health science	2019	15.72	4 Years
A study of Low Dose Bevacizumab with conventional radiotherapy OR Ultra-Low Dose Radiotherapy alone in Diffuse Intrinsic Pontine Glioma. (LoBULaR-DIPG)	Dr. Rahul Krishnatry	Reliance Life Sciences Pvt Ltd + BRAIN TUMOR FUND	Non-Government	Medical and Health science	2019	15.61	3 Years
Protocol No. - 0328-17 : A single arm, multicentric, open label, efficacy and safety study of Doceaqualip (Docetaxel Lipid Suspension for Injection of Intas Non-Governmentceuticals Limited, India) based regimens in metastatic gastric adenocarcinoma patients	Dr. Vikas Ostwal	Intas Non-Governmentceuticals Ltd., Corporate Office Bldg., Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad-380 054, Gujarat, India.	Non-Government	Medical and Health science	2019	82.29	3 Years 10 Months
Hematological Cancers Consortium: HCC Leukemia Registry	Dr. Manju Sengar	HCC	Non-Government	Medical and Health science	2019	116.84	10 Years
A prospective observational cohort study to identify the utility of risk-based screening strategy for long term complications in adolescent and adult cancer survivors of leukemia and lymphoma.	Dr. Hasmukh Jain	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	32.48	5 Years
Protocol No. - EGC002 : A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 (EirGenix Trastuzumab) with Herceptin® as Neoadjuvant Treatment in Combination with Anthracycline/Paclitaxel-based Systemic Therapy in Patients with HER2-positive Early Breast Cancer	Dr. Sudeep Gupta	Eirgenix Inc.	Non-Government	Medical and Health science	2019	264.00	4 Years
Evaluating The Role Of Genetic Susceptibility For Oropharynx Cancer In Indian Origin Population: a case-control study using the candidate gene approach	Dr. Sharayu Mhatre	ASCO (American Society of Cancer Oncology)	Non-Government	Medical and Health science	2019	20.18	4 Years

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin

कुलसचिव / REGISTRAR
होमि भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशाक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from dean-Academic of various CI's/OCC of HBSNI

Phase III trial of Observation versus Irradiation for a gross totally resected grade II Meningioma	Dr. Tejal Gupta	NRG Oncology/RTOG	Non-Government	Medical and Health science	2019	13.15	12 Years
Collaborative Action for Control of Cancer and Other Non-Communicable Diseases among Mumbai Police	Dr. Gauravi Mishra	Tata Trusts	Non-Government	Medical and Health science	2019	740.21	4 Years
Prevalence of Human Papilloma Virus in Spouses of Men diagnosed with Oral and Oropharyngeal Cancer	Dr. Gauravi Mishra	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	36.95	6 Years
COMPARISON OF TREATMENT ADHERENCE AND TOXICITIES OF HIV POSITIVE PATIENTS VS. HIV NEGATIVE CERVICAL CANCER PATIENTS IN INDIA	Dr. Lavanya Naidu	CRDF Global-ICMR	Non-Government	Medical and Health science	2019	83.03	3 Years
Health expenditure on breast cancer treatment in women: a study from public sector tertiary cancer centre (EXPERT).	Dr. Tabassum Wadasadawala	WCI-NAG foundation	Non-Government	Medical and Health science	2019	10.00	4 Years
Protocol No. - D933GC00001 : A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)	Dr. Vikas Ostwal	Astra Zeneca Non-Government India Ltd.	Non-Government	Medical and Health science	2019	57.70	4 Years
Phase III IGRT and SBRT vs IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer	Dr. Vedang Murthy	NRG Oncology	Non-Government	Medical and Health science	2019	84.73	6 Years
Protocol No. - CLEE011A3201C : A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptorpositive/HER2-negative inoperable locally advanced or metastatic breast cancer - RIGHT Choice Study	Dr. Sudeep Gupta	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical and Health science	2020	451.02	5 Years
A Phase II Randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic non small cell lung cancer patients-TARGET-1	Dr. Anil Tibdewal	DHR	Non-Government	Medical and Health science	2019	56.36	6 Years
A prospective observational study to compare speech and swallowing outcomes in patients undergoing treatment for oral tongue cancers	Dr. Shiva Kumar Thiagarajan	ICON	Non-Government	Medical and Health science	2019	10.00	3 Years

Compilation of data as received from various CI's/ocof. HONORABHA NATIONAL INSTITUTE
 प्रशिक्षण केंद्र/निदेशक परिसर, अणुशक्ती नगर, मुंबई - ४०० ०६४
 Training School Complex, Anushakti Nagar, Mumbai

Protocol No. - LUF-44-001 : Safety and Efficacy of Lipiodol® Ultra Fluid in Association with Surgical Glues during Vascular Embolization, a phase IV study	Dr. Suyash Kulkarni	Guerbet	Non-Government	Medical and Health science	2020	1.81	1 Years
Trastuzumab in HER2 positive Advanced Biliary tract cancers - single arm prospective phase II clinical trial (TAB trial)	Dr. Vikas Ostwal	Dr reddy' s LTD	Non-Government	Medical and Health science	2019	453.82	5 Years
Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study	Dr. Bhausahab Bagal	Amgen Inc	Non-Government	Medical and Health science	2019	122.98	4 Years 11 Months
Protocol No. - E7080-M091-507 : Prospective Single Arm Post Marketing Phase IV study to assess the Safety and Efficacy of Lenvatinib in Subjects with Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer	Dr. Vijay Patil	Eisai Non-Governmentceuticals India Pvt. Ltd.	Non-Government	Medical and Health science	2019	30.19	3 Years 1 Months
A study of HCC correlating its biology with Clinico demographic and ethnic features along with its Survival outcomes	Dr. Vikas Ostwal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	20.83	3 Years
A Prospective Observational Study of longitudinal assessment of neurocognitive function in patients with 1-4 brain metastases of NSCLC treated with Cranial Irradiation	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2019	14.04	4 Years
A New Method for Cervical Cancer Screening in Low- and Middle-Income Countries (LMIC): Training and Technical Validation of Automated Visual Evaluation (AVE) in India	Dr. Rajesh Dikshit	Clinton Health Access Initiative (CHAI), USA	Non-Government	Medical and Health science	2019	939.16	2 Years
HEmodynamic Resuscitation and Monitoring in Early Sepsis (HERMES Study)	Dr. Sheila Myatra	ISCCM	Non-Government	Medical and Health science	2019	1.00	2 Years 6 Months
Protocol No. - ALK18/ENZ124-CET1 : A prospective, multicenter, randomized, double blind, parallel group study to compare the efficacy and safety of biosimilar cetuximab versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN).	Dr. Kumar Prabhash	ALKEM LABORATORIES LIMITED	Non-Government	Medical and Health science	2019	146.84	2 Years 10 Months

Compilation of data as received from various CI's/OCC of M.S.N.I. Dr. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - QB46C-H03 : Exploratory Phase Ib/Ila Study of Intratumorally Administered Tigilanol Tiglate to Assess Safety, Tolerability and Tumour Response in Patients with Head and Neck Tumours	Dr. Gouri Pantvaidya	QBiotics Group Limited (QBiotics)	Non-Government	Medical and Health science	2019	70.66	4 Years
Protocol No. - CLEE011A2207 : A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease	Dr. Sudeep Gupta	Novartis Healthcare Pvt. Ltd.	Non-Government	Medical and Health science	2019	88.30	3 Years
Comparative performance evaluation of Artificial Intelligence (AI) based visual inspection test (AI_VIA) with Primary Health Worker administered VIA (PHW_VIA), HPV DNA test and cervical cytology to detect cervical pre-cancer lesions.	Dr. Sharmila Pimple	Periwinkle Technologies Pvt. Ltd., Pune	Non-Government	Medical and Health science	2019	6.68	3 Years
Protocol No. - NIS/2018/19 : An open label, single arm, multicentric, observational study to evaluate safety and effectiveness of Akynzeo®, an oral fixed dose combination of netupitant and palonosetron in the management of CINV, in the real world settings of India	Dr. Sudeep Gupta	Glenmark Non-Governmentceuticals Ltd.	Non-Government	Medical and Health science	2020	10.41	2 Years 6 Months
Carboplatin / Paclitaxel Versus Cisplatin/ Etoposide as Definitive Chemoradiotherapy for LocoRegionally advanced Non small Lung cancer (NSCLC): A Phase III Randomized Controlled Trial	Dr. Ajaykumar Singh	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	33.72	11 Years
Phase 3 non inferiority randomised study between low dose immunotherapy and cytotoxic chemotherapy in 2nd line or beyond setting in relapsed-recurrent or metastatic solid tumors	Dr. Rajendra Badwe	Trilokchand Papriwal Charitable Trust	Non-Government	Medical and Health science	2020	331.29	5 Years
A phase III randomized controlled trial of two radiotherapy fractionation regimens in metastatic epidural spinal cord compression in lung cancer patients	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	29.54	6 Years

Compilation of data as received from various CI's/OCC of HBNI

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin

कुलसचिव / REGISTRAR

होमी भाभा राष्ट्रीय संस्थान

HOMI BHABHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ८०४
Training School Complex, Anushakti Nagar, Mumbai

Protocol No. - MK3475-593-03 : A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with Unresectable or Metastatic Melanoma or PD-L1 positive Non-Small Cell Lung Cancer (NSCLC) in India (Keynote-593)	Dr. Jyoti Bajpai	MSD Non-Governmentceuticals Pvt Ltd	Non-Government	Medical and Health science	2020	456.11	5 Years
Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer- CompARE trial	Dr. Devendra Chaukar	University of Birmingham, Edgbaston, Birmingham, West Midlands, B15 2TT	Non-Government	Medical and Health science	2020	58.86	6 Years
A pilot study to determine the feasibility of detection of esophageal cancer by sponge cytology technique.	Dr. Sabita Jiwnani	Dr. Virginia R. Litle, Boston University, Collamore 7, Suite7380	Non-Government	Medical and Health science	2020	.08	2 Years 6 Months
An open label, prospective three-arm randomized, non-comparative study on efficacy and tolerability of orally disintegrating strip, oral tablets and intravenous administration of Vitamin B12, in post-gastrectomy Indian patients	Dr. Sujay Srinivas	EISAI Non-Government pharmaceuticals	Non-Government	Medical and Health science	2020	38.34	6 Years
Protocol No. - DRL-INDG02-PAN/2018 : An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize its Safety, Tolerability and Activity in Indian Subjects with Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer	Dr. Vikas Ostwal	Dr. Reddy's Laboratories Ltd.	Non-Government	Medical and Health science	2020	26.89	3 Years
Adjuvant chemotherapy for operated amPullary AdenoCarcinomas based on Histology and Intensification ; A two arm non - randomized open label prospective parallel adaptive design phase II clinical trial (APACHI)	Dr. Anant Ramaswamy	Educational Grant - Reliance Life Science / DAECTC	Non-Government	Medical and Health science	2020	11.20	7 Years
A randomized study to evaluate the effectiveness of Gabapentin on Oral-Mucositis induced pain due to chemo-radio therapy in patients with head and neck cancers.	Dr. Nandini Menon	CADILA	Non-Government	Medical and Health science	2020	21.22	3 Years
A phase II study to evaluate the role of short-course Pomalidomide in maintaining treatment-free remission post tyrosine-kinase inhibitor (TKI) discontinuation in adult patients with chronic myeloid leukemia-chronic phase (CML-CP).	Dr. Hasmukh Jain	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	84.00	

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशाक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from various CI'S/OCC of

Epithelial-mesenchymal transition (EMT) and Breast Cancer Stemness: Defining the role of OVOL and ACTN4 in cross talk	Dr. Omshree Shetty	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	26.14	2 Years
Grid Oncology: Remaking Cancer Care in India	Dr. C. S. Pramesh	Wellcome Trust	Non-Government	Medical and Health science	2020	30.36	3 Years
An open label, randomized, clinical trial of Mycobacterium w (Mw) as an Adjuvant to chemotherapy in Advanced Non-small Cell Lung Cancer	Dr. Kumar Prabhash	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	194.61	4 Years
Standard Maintenance Therapy versus Local Consolidation Radiation Therapy and Standard Maintenance Therapy In 1-5 sites of oligometastatic Non-Small Cell Lung Cancer (NSCLC) - A Phase III Randomized Controlled Trial (TARGET-2)	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	60.80	6 Years
A Prospective Observational Study on Outcomes of Bone Metastases treated with Radiotherapy in Lung Cancer	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	17.80	3 Years
Indian Pulmonary Embolism Registry (IndiPER)	Dr. Sohan Solanki	ETERNAL HOSPITAL JAIPUR	Non-Government	Medical and Health science	2020	15	3 Years
A randomized, open label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with standard triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy induced Nausea and vomiting in subjects with osteosarcoma and other solid tumors (OLAnzaPiNE)	Dr. Jyoti Bajpai	PROGRESSIVE LADIES WELFARE SOCIETY (NGO)	Non-Government	Medical and Health science	2020	5.29	2 Years
Phase I study to evaluate the feasibility and safety of addition of ruxolitinib to a standard BFM-90 regimen in adolescent/adult Ph-like ALL.	Dr. Hasmukh Jain	EM- LADY TATA MEMORIAL TRUST	Non-Government	Medical and Health science	2020	74.98	4 Years
Focal Radiotherapy Plus Low-Dose Craniospinal Irradiation Followed By Adjuvant Chemotherapy In WNT Subgroup Medulloblastoma (FOR-WNT 2 Study)	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	37.50	10 Years
Observation or upfront cranial RT in oncogene driver mutated NSCLC with asymptomatic brain metastases: A phase III Randomized Controlled Trial	Dr. Anil Tibdewal	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	85.60	6 Years
A prospective study to design therapeutic drug monitoring strategy for dasatinib in CML patients	Dr. Manjunath Nookala	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	34.09	3 Years

Compilation of data as received from various CI's/oc of HSNIE.

Dr. P. C. Sevilin / Prof. P. C. Sevilin

कुलसचिव / REGISTRAR

होमी भाभा राष्ट्रीय संस्थान

HOMI BHABHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९ ४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - D0816R00025 : A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA1/2 Mutation (SOLI Study)	Dr. Sudeep Gupta	Astra Zeneca Non-Government India Limited	Non-Government	Medical and Health science	2020	147.67	3 Years
Protocol No. - TX05-03E : A double-blinded extension study to provide adjuvant treatment with single agent Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03	Dr. Sushmita Rath	Tanvex Biologics Corp.	Non-Government	Medical and Health science	2020	116.24	2 Years
Protocol No. - D3614C00001 : A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC).	Dr. Sudeep Gupta	Astra Zeneca Non-Government India Limited	Non-Government	Medical and Health science	2020	545.53	2 Years 4 Months
Seroprevalence of COVID-19 in slum and non slum areas of Mumbai	Dr. Rajesh Dikshit	i-spirit	Non-Government	Medical and Health science	2020	201.01	3 Months
A phase II randomized study to evaluate the efficacy of short-course RR CVEP regimen against short course EPOCH-RR in adolescent and adult seropositive Diffuse large B cell lymphoma	Dr. Manju Sengar	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	139.65	3 Years
A pilot study of indigenously manufactured HCAR19 (2nd generation Anti-CD19-41BBCD3 (zeta) chimeric antigen receptor T-cell therapy) in adult patients with relapsed/refractory diffuse large B-cell lymphoma.	Dr. Hasmukh Jain	Immunoadoptive cell therapy private limited,	Non-Government	Medical and Health science	2020	75.54	10 Years
Angiotensin receptor blockade with losartan plus mFOLFIRINOX versus mFOLFIRINOX alone in advanced Pancreatic AdenoCarcinomas - a two arm open label prospective Phase III parallel design randomized superiority clinical trial (AFPAC)	Dr. Anant Ramaswamy	EM - LUPIN PVT LTD	Non-Government	Medical and Health science	2021	33.92	

Compilation of data as received from Dean-Academic

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कक्षाधिकारी / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९
 Training School Complex, Anushakti Nagar, Mumbai - 400 009

Protocol No. - D933AC00001 : A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi- Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1)	Dr. Vikas Ostwal	Astra Zeneca	Non-Government	Medical and Health science	2020	118.59	2 Years
A prospective, multicentre, post-marketing phase IV study to assess the safety and efficacy of Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC)	Dr. Vikas Ostwal	Eisai Non-Governmentceuticals, India Pvt. Ltd. 6th Floor, A Wing, Marwah Center, Krishanlal Marwah Marg, Andheri East, Mumbai 400072. Maharashtra, INDIA. Phon	Non-Government	Medical and Health science	2021	9.40	2 Years
AN OBSERVATIONAL STUDY TO DETERMINE THE ACCURACY OF OXYGEN RESERVE INDEX (ORI) TO PREDICT IMPENDING DESATURATION IN PATIENT'S UNDERGOING PROCEDURES UNDER APNOEA	Dr. Jeson Doctor	Smt KMD Medical Charitable Trust	Non-Government	Medical and Health science	2020	1.30	2 Years
Influence of Preoperative Vitamin-D, Serum Magnesium and Serum Phosphate levels on the development of transient and permanent hypocalcaemia and hypoparathyroidism following total thyroidectomy with or without central compartment clearance in patients with thyroid cancer (HypoCal Study).	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical and Health science	2020	18.33	4 Years
Higher vs. Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia: the COVID STEROID 2 trial	Dr. Jigeeshu Divatia	The George Institute for Global Health Plot No. 57, Second Floor, Corporation Bank Building Nagarjuna Circle, Punjagutta, Hyderabad - 500 082, Telanga	Non-Government	Medical and Health science	2020	6.00	2 Years
Protocol No. - ALK19/ENZ137-BEV1 : A prospective, multicenter, randomized, double blind, Phase III study to compare the efficacy and safety of Biosimilar Bevacizumab of Enzene Biosciences Ltd. versus Innovator Bevacizumab both in Combination with CAPEOX in Patients with Metastatic Colorectal Cancer.	Dr. Vikas Ostwal	Alkem Laboratories Limited, Alkem House, Senapati Bapat Marg, Lower Parel, Mumbai â€” 400013, Maharashtra , Enzene Biosciences Limited, Plot Number	Non-Government	Medical and Health science	2021	13.18	2 Years 4 Months

Compilation of data as received from Dean-Academic of various *Dr. P. C. Sarin*

Dr. P. C. Sarin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान

HOMI BHABHA NATIONAL INSTITUTE
शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - D133HC00003 : A prospective, multicenter, Phase-IV clinical trial to assess safety of Durvalumab in Indian adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) and urothelial cancer	Dr. Nandini Menon	Astra Zeneca	Non-Government	Medical and Health science	2021	79.65	2 Years 6 Months
ECHO Telementoring to Improve Quality Palliative Care in Underserved Areas of Zambia, Kenya, Nigeria, Ghana, South Africa, and India.	Dr. Jayita Deodhar	M D Anderson Cancer Centre	Non-Government	Medical and Health science	2021	29.51	2 Years
Evaluation of the safety and efficacy of generic low-dose Dasatinib for frontline therapy in chronic phase chronic myeloid leukemia - A multi-center phase II single arm study	Dr. Hasmukh Jain	Hematology Cancer Consortium	Non-Government	Medical and Health science	2021	12.67	2 Years
Protocol No. - 61186372NSC3001 : A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.	Dr. Vijay Patil	Johnson and Johnson Private Limited	Non-Government	Medical and Health science	2021	79.77	2 Years 6 Months
TMH IRIS: Proposal for participation of TMH ICU in the Indian Registry of Intensive care (IRIS)	Dr. Atul Kulkarni	Chennai Critical Care Consultants Group	Non-Government	Medical and Health science	2021	2.61	2 Years
Protocol No. - 73841937NSC3003 : A Phase 3, Randomized study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated LocallyAdvanced or Metastatic Non-Small Cell Lung Cancer	Dr. Vijay Patil	Johnson & Johnson Private Limited	Non-Government	Medical and Health science	2021	114.10	2 Years 6 Months
A Phase 4 Study of Nivolumab in Combination with Ipilimumab in Patients with PreviouslyUntreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk FactorsConducted in India	Dr. Amit Joshi	Bristol-Myers Squibb Research and Development	Non-Government	Medical and Health science	2021	101.07	3 Years
Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC)	Dr. Swapnil Rane	NIH	Non-Government	Medical and Health science	2021	130.96	5 Years
Prophylactic pirfenidone for prevention of radiation induced pneumonitis in patients with Lung cancer (PROPER study)	Dr. Naveen Mummudi	TMC-Corporate Research fund	Non-Government	Medical and Health science	2021	1.00	2 Years

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin

Compilation of data as received from Dean-Academic of the REGISTRAR'S OFFICE
होमी भाभा राष्ट्रीय संस्थान
of HBNI.

RBH

HOMI BHABHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशास्त्री नगर, मुंबई - ४०० ०९४

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2).	Dr. Vikas Ostwal	Astra Zeneca	Non-Government	Medical and Health science	2021	66.57	3 Years
COVID-19 with Hematological Cancers Registry of India (CHCRI)	Dr. Lingaraj Nayak	Hematology Cancer Consortium (HCC)	Non-Government	Medical and Health science	2021	1.08	1 Years 6 Months
Evaluating Immunohistochemical and Molecular Landscape of Select Osteoclastic Giant Cell Rich Tumors of the Bone	Dr. Bharat Rekhi	TMC-Corporate Research fund	Non-Government	Medical and Health science	2021	12.38	2 Years
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02).	Dr. Vikas Ostwal	Astra Zeneca	Non-Government	Medical and Health science	2021	18.71	3 Years
Evaluation of the effect of foot bathing on peripheral neuropathy in patients receiving oxaliplatin containing chemotherapy for GI cancer at Tata Memorial Hospital	Mrs. Anita D Souza	IASCC	Non-Government	Medical and Health science	2021	2.41	3 Years
Early T-cell precursor acute lymphoblastic leukaemia: Unravelling mechanisms of resistance and development of novel therapeutic strategies	Dr. Manju Sengar	Lady Tata Memorial Trust	Non-Government	Medical and Health science	2021	197.82	4 Years
Protocol No. - D967JC00001 : A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with other Anti-cancer Agents in Patients with HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)	Dr. Sudeep Gupta	Astra Zeneca	Non-Government	Medical and Health science	2021	144.14	3 Years
Avoiding prophylactic growth factors during paclitaxel phase of dose dense adjuvant chemotherapy in breast cancer	Dr. Seema Gulia	Indian Association of Supportive Care	Non-Government	Medical and Health science	2021	3.00	2 Years
Obesity and non-communicable disease in India: an imaging study of 10,000 adults in the Indian Study of Healthy Ageing (ISHA cohort study).	Dr. Sharayu Mhatre	CTSU UK, UNIVERSITY OF OXFORD	Non-Government	Medical and Health science	2021	190.24	3 Years

Compilation of data as received from Dean-Academic of the *veerabai* *Prof. P/BCC* *Self up*
कुलसचिव / REGISTRAR

रव होमी भाभा राष्ट्रीय संस्थान *MBNI*
HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Pilot study for measurement of intra-tumoral interstitial fluid pressure in various cancers	Dr. Qurratulain Ali Chougale	TMC-Corporate Research fund	Non-Government	Medical and Health science	2021	53.76	2 Years
Prevalence, predisposing factors and management of Head and Neck Lymphedema in patients following treatment for Head and Neck Cancer. (HeNly-1 Study)	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical and Health science	2021	8.22	4 Years
Protocol No. - D9311C00001 : A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)	Dr. Sudeep Gupta	Astra Zeneca	Non-Government	Medical and Health science	2021	200.86	4 Years
An open label phase III randomized clinical trial of pomalidomide cyclophosphamide and dexamethasone versus pomalidomide dexamethasone in relapsed/ refractory multiple myeloma treated with lenalidomide and a proteasome Inhibitor.	Dr. Lingaraj Nayak	TMC-Corporate Research fund	Non-Government	Medical and Health science	2021	19.30	3 Years 10 Months
A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)	Dr. C. S. Pramesh	Astra Zeneca	Non-Government	Medical and Health science	2021	63.56	7 Years 6 Months
The Clinical Value of Ultrasound based Navigation update in cranial resection procedures	Dr. Aliasgar Moiyadi	Brainlab AG	Non-Government	Medical and Health science	2021	33.25	2 Years
A Phase 2 Basket Study of the Oral TRK Inhibitor larotrectinib in Subjects with NTRK Fusion-Positive Tumors(NAVIGATE)	Dr. Vikas Ostwal	Non-US: Bayer Consumer Care AG, Peter-Merian-Strasse 84, 4052 Basel, Switzerland US-territory: Bayer HealthCare Non-	Non-Government	Medical and Health science	2021	51.25	3 Years

Compilation of data as received from Dean-Academic of various CI's/OCC of HBNL

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE
प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

A randomized phase III clinical trial evaluating the non-inferiority of reduced dose chemotherapeutic regimens based on CARG risk scores compared to standard doses in Older patients with advanced esophageal, esophagogastric, gastric, and biliary tract cancers (CARGO study)	Dr. Anant Ramaswamy	TMC-Corporate Research fund	Non-Government	Medical and Health science	2022	60.10	6 Years
Preventing Cervical Cancer in India through self-sampling (PCCIS)	Dr. Gauravi Mishra	Fund for Innovation and Transformation, program of the Inter-Council Network of Provincial and Regional Councils (ICN), Global Affairs Canada.	Non-Government	Medical and Health science	2021	65.95	1 Years 3 Months
Protocol No. - D8220C00022 : A prospective, multi-centre, phase IV clinical trial to assess the safety and efficacy of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukemia and relapsed and refractory mantle cell lymphoma	Dr. Manju Sengar	Astra Zeneca	Non-Government	Medical and Health science	2021	29.45	2 Years
Impact of on-demand training & audio-visual aids to improve referral rates for genetic counselling and/ testing at a tertiary cancer centre (Mainstreaming Study)	Dr. Rima Pathak	Astra Zeneca	Non-Government	Medical and Health science	2022	10.00	2 Years
A Multicountry, Multicentre, Non-interventional, Prospective Study to Determine the Prevalence of EGFR Mutations in Patients with Early-stage, Surgically Resected, Non-squamous, Non-small Cell Lung Cancer	Dr. Vijay Patil	Astra Zeneca	Non-Government	Medical and Health science	2022	3.00	1 Years
Psychological distress in adolescents and young adults (AYA) with cancer referred to Psycho-oncology service: a single centre prospective observational study in a low middle income country setting	Dr. Jayita Deodhar	TMC-Corporate Research fund	Non-Government	Medical and Health science	2022	12.82	2 Years
Immunohistochemical analysis of LLT1 on prostate cancer biopsy samples	Dr. Santosh Menon	Zumutor Biologics	Non-Government	Medical and Health science	2021	4.58	1 Years
Women Empowerment-Cancer Awareness Nexus (WE-CAN): An Implementation Research Study of Cervical Cancer Prevention through HPV Self-Sampling and Education in India	Dr. Gauravi Mishra	Indian Medical Council of Research (ICMR) & Canadian Institutes of Health Research (CIHR) under Global Alliances for Chronic Diseases(GACD)	Non-Government	Medical and Health science	2021	1571.48	5 Years

Compilation of data as received from Dean-Academic of *Dr. P. C. Selyia* Registrar of *HNSI*

Dr. P. C. Selyia
 Registrar
 Homi Bhabha National Institute
 Homi Bhabha National Institute
 Training School Complex, Anushakti Nagar, Mumbai - 400 098

A randomized, double-blind, placebo-controlled Phase 3 study of Darolutamide in addition to androgen deprivation therapy (ADT) versus placebo ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).	Dr. Amit Joshi	Covance India Non-Governmentceutical Services Pvt. Ltd.	Non-Government	Medical and Health science	2021	439.17	3 Years
An Open-label, Multicenter, Randomized Phase 3 Study of First line Encorafenib Plus Cetuximab With or Without Chemotherapy versus Standard of Care Therapy with a Safety Lead-in of Encorafenib and Cetuximab Plus Chemotherapy In Participants with Metastatic BRAF V600E Mutant Colorectal Cancer	Dr. Vikas Ostwal	PFIZER	Non-Government	Medical and Health science	2021	60.88	3 Years
Protocol No. - WO42633 : A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY (ASTEFANIA STUDY).	Dr. Sudeep Gupta	Roche Products (India) Pvt. Ltd.	Non-Government	Medical and Health science	2022	505.21	10 Years
Protocol No. - DP-1111-02CT : A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)	Dr. Venkatesh Rangarajan	ITM Solucin GmbH	Non-Government	Medical and Health science	2022	94.45	10 Months 1 Days
REal-World treatment outcomes for Asian breast cancer paTiEnt (REWRITE Study)	Dr. Seema Gulia	Novartis Oncology Novartis (Thailand) Limited	Non-Government	Medical and Health science	2022	14.66	1 Years
Developing precision immunotherapy for value-based treatment of lung cancer in India	Dr. C. S. Pramesh	DBT/Wellcome Trust india Alliance	Non-Government	Medical and Health science	2021	999.10	5 Years

Compilation of data as received from Dean - Academic *Prof. P. C. Selvin* / REGISTRAR / Secy of HSNL.

Rohit

HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - GO42784 : A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Adjuvant Giredestrant Compared With Physician's Choice Of Adjuvant Endocrine Monotherapy In Patients With Estrogen Receptor-Positive, Her2-Negative Early Breast Cancer	Dr. Sudeep Gupta	Hoffmann-La Roche Ltd	Non-Government	Medical and Health science	2022	520.90	10 Years
PERioperative respiratory care and outcomes for patieNts Undergoing high risk abdomiNal surgery	Dr. Sohan Solanki	University of Birmingham	Non-Government	Medical and Health science	2022	1.80	2 Years
Protocol No. - D0817R00044 : A non-interventional, multicenter study to determine the prevalence of homologous recombination repair (HRR) gene mutation in patients with metastatic castration-resistant prostate cancer in India	Dr. Nandini Menon	Astra Zeneca	Non-Government	Medical and Health science	2022	11.25	1 Years 6 Months
A Multi-country, Multi-centre, Non-interventional, REtrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant PROstate Cancer.	Dr. Amit Joshi	Astra Zeneca	Non-Government	Medical and Health science	2022	8.65	1 Years
Evaluation of Adequacy of Pain Relief and Medications Used in Pain Management in Cancer Patients Attending Palliative Medicine Out-Patient Department in a Tertiary Care Hospital	Dr. Raghu Thota	Research Society KEM Hospital	Non-Government	Medical and Health science	2022	.07	1 Years
National Postdoctoral Fellowship	Dr. Antarjami Sahoo (NPDF) under mentorship of Dr. Subhankar Bedanta	Jawaharlal Nehru Centre for Advanced Scientific Research	Non-Government	Chemical Sciences	2021-2022	6.46	2 years
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel versus Weekly Paclitaxel Plus Weekly Carboplatin in Women with Triple Negative Breast Cancer	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2009	65.40	13 Years
Image Guided Radiation Therapy (IGRT) in Cervical Cancers	Dr. Umesh Mahantshetty	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2011	20.16	10 Years 1 Months 6 Days
Randomized controlled trial to assess blockade of voltage gated sodium channels during surgery in operable breast cancer	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2011	73.06	13 Years
Prevalence of malnutrition in patients with lung cancer	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2015	10.53	5 Years

Compilation of data as received from Dean-Academic of various IITs / IISc / IISER / IITM / IITK / IITR / IITG / IITJ / IITKGP / IITB / IITD / IITM / IITK / IITR / IITG / IITJ / IITKGP / IITB / IITD

Prof. P. G. Selvin / कुलसचिव / REGISTRAR
HOMI BHABHA NATIONAL INSTITUTE
अनुशास्त्रीय विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
School Complex, Anushakti Nagar, Mumbai - 400 094

Prospective Phase III randomized trial of prostate only or whole pelvic radiotherapy in high risk prostate cancer (POP-RT trial)	Dr. Vedang Murthy	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2011	19.92	11 Years
Phase III non-inferiority randomized trial comparing three-weekly Cisplatin versus weekly Cisplatin in combination with radiation therapy in patients with advanced carcinoma of the head and neck	Dr. Vanita Noronha	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2012	45.93	11 Years
A Phase III Double Blind Randomized Placebo Controlled study of Trastuzumab as Short Duration Preoperative Therapy in patients with HER2-neu Positive Operable Breast Cancer	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2012	52.63	11 Years
Randomised controlled trial assessing addition of neoadjuvant and maintenance oral metronomic chemotherapy to standard surgery and adjuvant therapy in Stage III/IV Operable Oral cancers	Dr. Prathamesh Pai	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2012	79.74	11 Years
Phase II Randomised Controlled Trial Of Postoperative Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Thyroid Cancers	Dr. Gouri Pantvaidya	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2012	22.17	14 Years
Demographic profile of lung cancer and its treatment in India	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2012	2.96	10 Years
Comparative study for efficacy and safety of Paclitaxel with Cisplatin/Carboplatin versus 5-Fluorouracil with Cisplatin/Carboplatin in resectable carcinoma esophagus or gastroesophageal junction carcinoma	Dr. Kumar Prabhash	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2013	3.78	9 Years 10 Months
Prospective Screening log for patients with recurrent or second primary Head and Neck Cancers referred for re-Radiotherapy.	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2014	6.40	9 Years
Ophthalmic Outcomes After Treatment of Paranasal sinus Tumors	Dr. Devendra Chaukar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2013	.35	8 Years 3 Months 22 Days
Observational study to evaluate the outcome of prescreen failure and screen failure patients who receive chemoradiation for locally advanced Head and Neck Cancer	Dr. Vanita Noronha	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2014	8.64	9 Years
Pilot study to assess the presence of hypoxia related biomarkers in patients with oral cancer	Dr. Gouri Pantvaidya	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2014	53.85	9 Years

Compilation of data as received from Dean - Academic of the various CIS/OCC
 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR HBNI.

RBH

होमी भाभा राष्ट्रीय संस्थान

HOMI BHABHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४

Training School Complex, Anushakti Nagar, Mumbai - 400 094

A Prospective Study To Evaluate The Incidence Of Peripheral Neuropathy In Taxane Based Chemotherapy In Epithelial Ovarian Carcinoma	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2014	1.92	6 Years
Germ Cell tumor outcome and long term follow up study (GTOF)	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2014	5.04	8 Years
Prevalence and predictors of malnutrition and its impact on quality of life in patients with Gastric cancer - a single centre prospective study	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2014	21.00	8 Years
Prospective non-randomized study to compare accuracy of clinical examination under anesthesia, axillary ultrasound and histopathological examination for axillary nodal staging in women with clinically NO early breast cancer.	Dr. Vani Parmar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2015	3.75	8 Years
Feasibility and implications of thoracoscopic dissection of internal mammary nodes in central and inner quadrant breast cancer	Dr. Sabita Jiwnani	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2015	35.27	8 Years
Utility of pectoralis major myofascial flap in reducing pharyngocutaneous fistula rates after salvage total laryngectomy.	Dr. Devendra Chaukar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2015	28.41	9 Years
Phase III randomized trial of high dose chemoradiation and systemic chemotherapy vs systemic chemotherapy alone in patients with unresectable nonmetastatic cholangiocarcinoma	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2015	105.61	8 Years
Comparison of incidence of precursor and pre-invasive lesions of the gall bladder in patients operated for chronic cholecystitis and cholelithiasis in endemic and non-endemic regions in India.	Dr. Mukta Ramadwar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2015	56.77	7 Years
Prospective Pilot Study:Oncologic safety and Functional outcome following Neo-adjuvant Chemotherapy in T2-T4a Tongue cancers	Dr. Prathamesh Pai	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2015	39.06	6 Years
Survivorship programme for colorectal cancers patients- a randomized study	Dr. Avanish Saklani	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2015	25.00	10 Years
Role of electrochemotherapy for head and neck and breast cancers in a palliative setting	Dr. Devendra Chaukar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2015	2.03	6 Years 7 Months 20 Days
Study of quality of life of CA Ovary patients from a tertiary care cancer centre	Dr. Jyoti Bajpai	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2016	4.51	7 Years

Compilation of data as received from Dean - Academic of the various CI's/OCC
 प्र. पा. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR of HBNI.

HOMI BHABHA NATIONAL INSTITUTE

शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Education School Complex, Anushakti Nagar, Mumbai - 400 094

Conventional Radiography based Intracavitary Brachytherapy (Standard Arm) versus Magnetic Resonance Image based BrAchyTherapy (Study Arm) in Locally Advanced Cervical Cancers: A Phase III Randomized Controlled Trial (COMBAT - Cervix Trial)	Dr. Lavanya Naidu	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2016	146.40	7 Years
NIS expression detection in metastatic breast cancer with 131I NaI	Dr. Venkatesh Rangarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2016	3.00	5 Years 3 Months
A prospective study to evaluate the feasibility of hippocampal sparing intensity modulated radiotherapy in preserving neurocognitive functions in adult patients with pituitary adenoma.	Dr. Jayant Goda	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2016	4.45	7 Years
Perioperative therapy (preop chemo v/s CRT) in locally advanced gall bladder cancers (POLCA-GB)	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2016	70.28	7 Years
Performance of HPV DNA Test in presence of co-infection with common RTIs	Dr. Sharmila Pimple	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2016	6.69	6 Years 6 Months
Randomized trial of effect of two fractionation schedules of Adjuvant Radiation following Immediate Autologous Breast Reconstruction (ARIA-BR) on Toxicity and Patient Reported Outcome Measures.	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2016	40.85	8 Years
Audit of clinical outcomes of adjuvant whole breast or chest wall with or without regional irradiation in women of breast cancer treated with different fractionation schedules over two years.	Dr. Ashwini Budrukkar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2016	3.60	6 Years
Acceptability and validity of self sampling for high risk HPV detection among women in Maharashtra	Dr. Gauravi Mishra	PHFI THROUGH THE PH LEADER PRPGRAMME	Non-Government	Medical & Health Science	2017	75.62	6 Years 2 Months
Efficacy and tolerability of two different bowel preparation regimens for pre-colonoscopy bowel cleansing in treatment naive Indian patients with colorectal cancer; a single center prospective randomized single blind study	Dr. Shaesta Mehta	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2016	8.74	3 Years
Adjuvant Radiotherapy in Early Stage Oral Cancers (AREST) -a prospective randomized control trial	Dr. Sudhir Vasudevan Nair	National Cancer Grid	Non-Government	Medical & Health Science	2016	418.37	7 Years
Study of the Nephron Sparing Surgeries done at Tata Memorial Hospital	Dr. Mahendra Pal	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2016	.40	8 Years

Compilation of data as received from Dean- Academic of the प्रो. आ. सा. साखिन / Prof. A. C. Sawin's/oc
of HBNI कुलसचिव / REGISTRAR
होमी भाभा राष्ट्रीय संस्थान
HOMI BHABHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
Training School Complex, Anushakti Nagar, Mumbai - 400 094

Protocol No. - NA : Image guided intensity modulated External beam Radiotherapy and MRI based adaptive Brachytherapy in Locally advanced Cervical Cancer. EMBRACE-II	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2016	48.25	9 Years
Efficacy of Bortezomib and Rituximab in newly diagnosed adolescent and adult CD20 positive Philadelphia (Ph) negative Precursor B-cell acute lymphoblastic leukemia: Phase II study	Dr. Manju Sengar	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2017	82.94	6 Years
Histopathologic and Immunohistochemical Features of Solitary Fibrous Tumors of Soft Tissues	Dr. Bharat Rekhi	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2016	8.72	4 Years 1 Months
Clinicohistopathological correlation of esthesioneuroblastoma and assessment of prognostic impact of expression of apoptosis markers cleaved Caspase 3, XIAP, Survivin and proliferative marker Ki-67	Dr. Asawari Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2016	8.87	6 Years
A Feasibility and Safety Study of Single Application Multifractionated High Dose Rate Brachytherapy in Locally Advanced Cervical Cancer	Dr. Lavanya Naidu	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2017	26.06	4 Years
A prospective COhort study of breast cancer patients with New bone metastases to estimate QQuality of life, health Economics & Risk of skeletal complications (CONQUER)	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2017	27.70	6 Years
A comparison of clinicopathological profile of non-B non-C hepatocellular cancer (HCC) and Hepatitis B or C related HCC	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2017	.18	6 Years
Effect of Pre Operative Distress Levels on Post Surgical Wound Healing in Head Neck Squamous Cell Carcinoma Patients	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2018	3.23	4 Years 6 Months
Clinicopathologic Features of Undifferentiated Round CellSarcomas of Bone and Soft Tissues	Dr. Bharat Rekhi	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2017	8.08	5 Years 6 Months
A randomized controlled trial to evaluate the safety of breast conserving surgery post neo-adjuvant therapy locally advanced breast cancer.	Dr. Nita Nair	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2018	12.07	12 Years
A cross-sectional feasibility study of a telephonic questionnaire by research nurses for follow-up of locally advanced cervical cancer patients with complete response to treatment	Dr. Lavanya G	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2018	3.84	5 Years

Compilation of data as received from Dean - Academic of *various* *of* *MBNI*

डॉ. पी. सी. सेल्विन / Prof. P. C. Selvin
 कलमविप / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Evaluating the clinical utility of new immunophenotypic markers in the determination of minimal residual disease in childhood acute myeloid leukemia.	Dr. Prashant Tembhare	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2018	4.03	5 Years
Pilot study to evaluate the biodistribution & dosimetry of ¹⁷⁷ Lu - Trastuzumab in HER2 receptor positive metastatic breast carcinoma and its toxicity & efficacy profile	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2018	122.99	5 Years
Esophagectomy Complications Platform and Quality Measures: What is the Contemporary Incidence of Complications at High Volume Esophagectomy Centers?	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2018	23.57	10 Years
Utility of MRI in evaluation of pancreatic cancer for predicting and assessing response to neoadjuvant chemotherapy: A prospective observational study	Dr. Akshay Baheti	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2018	4.15	5 Years
Acupuncture as a modality of treatment for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer-A Phase 3 Randomized Controlled Trial (ABC-CIPN).	Dr. Jyoti Bajpai	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2018	4.72	5 Years
Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children with Acute Lymphoblastic Leukemia: A Pilot Study	Dr. Maya Prasad	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2018	61.22	5 Years
Prevalence and predictors of malnutrition and its impact on quality of life and prognosis in patients with hepato-biliary tumors - a prospective study	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2018	20.79	5 Years
Prevalence and predictors of malnutrition and its impact on quality of life and prognosis in patients with pancreatic tumours - a prospective study	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2018	29.16	5 Years
A randomized clinical trial evaluating the efficacy and safety of the addition of postoperative chemoradiation versus observation in patients with high-risk esophageal squamous cell carcinoma following surgery	Dr. Devayani Niyogi	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	300.32	12 Years
Establishment of national gall bladder cancer registry	Dr. Mahesh Goel	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2018	18.77	6 Years
A Phase 2 randomized controlled trial to evaluate the role of modified C.O.M.B.A.T maintenance regimen in children with high risk medulloblastoma	Dr. Girish Chinnaswamy	Terry Fox Foundation	Non-Government	Medical & Health Science	2018	58.42	4 Years

Compilation of data as received from Dean - Academic of the प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR I S/OCC of
 होमी भाभा राष्ट्रीय संस्थान HBNL.

Precision medicine and Malnutrition- A Model based approach to dose chemotherapy in pediatric patients with malnutrition	Dr. Girish Chinnaswamy	Terry Fox Foundation	Non-Government	Medical & Health Scienc	2018	172.91	5 Years
A randomized phase 2/3 trial of Rosuvastatin with neo-adjuvant chemo-radiation in patients with rectal cancer	Dr. Prachi Patil	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2018	124.20	7 Years
Effect Of Pre-Operative Transarterial Embolisation On Circulating Tumor Cells And Recurrence In Hepatocellular Carcinoma	Dr. Mahesh Goel	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2019	13.70	4 Years
A Double Blind Randomized Controlled Trial of Renal Protective Effects of Normal Saline Plus Placebo Versus Normal Saline Plus Mannitol Prior to Cisplatin Containing Chemotherapy Regimens in Osteosarcoma and other Solid Tumors.	Dr. Jyoti Bajpai	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2018	34.41	4 Years
Revisiting grading of squamous carcinoma using computational methods	Dr. Swapnil Rane	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2018	11.75	5 Years
Feasibility Of Magnetic Resonance Image Based Target Delineation In Radical High Dose Rate Interstitial Brachytherapy For Early Oral Cavity Cancers: A Pilot Study	Dr. Ashwini Budrukkar	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2018	1.42	4 Years
Prospective cohort study to determine the association of pre-operative nutritional status with 90 days morbidity among patients undergoing Radical cystectomy or Radical Cysto-Prostatectomy for Bladder Cancer	Dr. Mahendra Pal	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2019	.11	4 Years 6 Months
Pilot Study to standardize the technique of Dynamic Sentinel Lymph Node Biopsy in management of penile cancer patients with clinically normal groin	Dr. Gagan Prakash	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2019	3.87	3 Years
Effect of intravenous iodinated contrast media on renal function in adults with estimated glomerular filtration rate <45 mL/min/1.73m ² : A randomized controlled non-inferiority trial	Dr. Akshay Baheti	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2018	62.01	4 Years
Biomarker-based optimization of adjuvant therapy in glioblastoma	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2018	270.90	5 Years
A Pilot Study of CONcurrent ChEmotherapy and RadioTherapy in Adjuvant Treatment of Breast Cancer (CONCERT)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2018	6.66	5 Years
Rapid Palliation in Locally Advanced Cervical Cancer: A Phase III randomized trial (RAPPAL Study)	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Scienc	2019	71.52	Years

Compilation of data as received from Dean - Academic of various ^{होमि भाभा राष्ट्रीय संस्थान} HBNi

डॉ. पी. सी. सेल्विन / Prof. P. C. Selvin
 कलमजि / REGISTRAR
 HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, अणुशाक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

Inflammatory Indices in Diffuse Glioma (InDiGo): A Prospective Observational Study	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2018	3.57	6 Years
Androgen blockade - Is this the missing link between mucinous micro-papillary carcinoma and micro-papillary carcinoma of breast.	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	40.57	4 Years
A Prospective Randomised trial to assess the clinical utility of TMH Mini Quality of Life (TMQ) questionnaire	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	3.00	3 Years
HIPEC after Neoadjuvant Chemotherapy in Frontline Treatment of Advanced Epithelial Ovarian, Fallopian tube or Primary Peritoneal Cancer: A Phase III Randomized Controlled Trial	Dr. Amita Maheshwari	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	253.35	6 Years
Clinical effect of vaporized Cannabinoids on Breast cancer genetic Expression patterns in the peri-operative period (CABREX study)	Dr. Rajendra Badwe	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	68.70	4 Years
A phase II study of hormone therapy alone in low-grade serous cancer (ovary/fallopian tube/peritoneum) following debulking surgery	Dr. Seema Gulia	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	25.50	6 Years
Prevalence of cardiovascular diseases in long term Breast Cancer survivors	Dr. Sheela Sawant	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	20.64	6 Years
Phase III, Assessor blinded, randomised controlled trial of the use of intraoperative neuromonitoring (IONM) in thyroid cancer surgery	Dr. Gouri Pantvaidya	TERRY FOX	Non-Government	Medical & Health Science	2019	30.09	5 Years
Establishing an in house, cost effective, TMH Predict gene panel for Prognosis and Prediction in Breast Cancer Patients subjected to adjuvant therapy.	Dr. Omshree Shetty	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	21.50	3 Years
A Prospective Phase III open label Randomized Controlled Trial evaluating the role of Neoadjuvant chemotherapy in mandible preservation in oral cavity cancers	Dr. Devendra Chaukar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	377.59	6 Years
Dose Escalated Radiotherapy and Organ Preservation in Rectal Cancers (DEROP-RC)	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	28.57	4 Years
Neoadjuvant treatment versus upfront surgery in Resectable pancreatic cancer (NEVUS)	Dr. Reena Engineer	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	74.40	5 Years

Compilation of data as received from Dean-Academic of various CI's/OCC of HSNIE
 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

A double arm, phase-III randomised study to assess the effect of Resveratrol-Copper in reducing oral mucositis in patients receiving concurrent chemo-radiotherapy for locally advanced oral cavity and oropharyngeal cancers	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	51.55	5 Years
A Prospective Randomized Phase III Trial of Short Course Versus Long Course Local Radiotherapy in patients with Multiple Myeloma symptomatic for Pain (ProM)	Dr. Nehal Khanna	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	81.51	6 Years
PRECedeNT trial: Phase III randomised-controlled open-label trial of Lutetium - 177 Peptide Receptor Radionuclide Therapy (PRRT) Plus Chemotherapy Versus PRRT alone in FDG-avid, Well-Differentiated Gastro-Enteropancreatic Neuroendocrine Tumors (GEP-NETs)	Dr. Ameya Puranik	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	24.00	8 Years
Effect of nurse led intervention on cognitive and non-cognitive functions and serum TNF alpha levels in patients receiving chemotherapy for CRC at Tata Memorial Hospital, Mumbai	Mrs. Anita D Souza	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	15.87	3 Years
Classical Hodgkins lymphoma(CHL) with primary marrow presentation- does it use immune escape mechanism to hide ?	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	6.12	1 Years
A prospective study to evaluate the Adverse Drug Reactions and to assess quality of life in prostate cancer patients receiving docetaxel in Tata Memorial Centre.	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	10.42	4 Years
Prevalence and impact of Vitamin D deficiency on the treatment outcomes of Head and Neck squamous cell carcinoma patients.	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	30.00	4 Years
Assessment of financial burden in patients with head and neck cancer undergoing curative intent treatment	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	3.00	3 Years 9 Months
Evaluation of Organ filling (rectum and bladder) and Comprehensive Adaptive Radiotherapy using daily imaging by CBCT during radical radio(chemo)therapy for locally advanced cervical cancers.	Dr. Lavanya G	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	35.12	3 Years 6 Months
Intra-operative recurrent laryngeal nerve monitoring during three field esophagectomy-a pilot study	Dr. Sabita Jiwnani	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	11.92	3 Years

Compilation of data as received from Dean-Academic of Various *Colleges* / Prof. P. C. Selvin
कुलसचिव / REGISTRAR

होमी भाभा राष्ट्रीय संस्थान HBNZ

HOMI BHABHA NATIONAL INSTITUTE

विश्वविद्यालय परिसर, अणुशास्त्री मार्ग, मुंबई - ४०० ०९४

20/10/2019

A study of factors associated with delayed presentation of patients with Testicular Germ Cell Tumors for seeking specialized care at Tata Memorial Hospital. (DeLP-GCT)	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2019	.10	4 Years
A prospective pilot study to evaluate the success of LYMPHA (Lymphatic Microsurgical Preventive Healing Approach) in women undergoing Axillary dissection for breast cancer	Dr. Vinay Shankhdhar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	2.54	3 Years
Impact of Tumor Bed Boost Technique on Toxicity and Aesthetic Outcomes after Breast Conservation Therapy: A Prospective Longitudinal Study	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	9.85	5 Years
Patient perception of 'meaningful benefit' from palliative chemotherapy in metastatic lung cancer - A survey	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	2.15	4 Years
A Prospective, Observational study to Compare Quality of Life and side effects in patients undergoing Medical versus Surgical Castration in Metastatic Carcinoma of Prostate at Tata Memorial Hospital	Dr. Amit Joshi	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	12.22	4 Years
Development and Implementation of Artificial Intelligence Technology for Validated Risk Prediction Model for Different Stages of Oral Cavity Squamous Cell Carcinoma	Dr. Pankaj Chaturvedi	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	73.60	3 Years
Phase 1 study of safety and feasibility of Ayurvedic oral cannabis preparation in the peri-operative period in oral cavity squamous cell cancer	Dr. Shiva Kumar Thiagarajan	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	86.56	2 Years
Growth, Endocrine And Reproductive Late Effects In Long-Term Survivors Of Childhood Cancers: A Prospective Observational Study	Dr. Maya Prasad	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	26.59	5 Years
Assessment of Surgical margins in BCS using Intraoperative imaging Techniques (ASSIST)	Dr. Nita Nair	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	5.39	3 Years
A randomized controlled trial to Assess the incidence of lymphedema in women with breast cancer undergoing Sentinel lymph node biopsy or Low axillary sampling. (AiSLe)	Dr. Nita Nair	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	9.92	3 Years
A study evaluating the efficacy of axillary reverse mapping in biopsy proven patients undergoing upfront surgery.	Dr. Vani Parmar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	2.90	3 Years

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin

कुलसचिव / REGISTRAR

श्री. मा. पा. राष्ट्रीय संस्थान

HOMI BHABHA NATIONAL INSTITUTE

प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४

Training School Complex, Anushakti Nagar, Mumbai - 400 094

Compilation of data as received from Dean-Academic of various schools of HBNM

Randomized control trial to test Pre-exposure prophylaxis (PREP) with oral Acyclovir to prevent chickenpox in varicella-seronegative children with hematolymphoid malignancies receiving intensive chemotherapy at Tata Memorial Hospital	Dr. Chetan Dhamne	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2021	28.79	2 Years
Posterior fossa Ependyomas: a study on molecular subgrouping	Dr. Sridhar Epari	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	27.97	2 Years
Treating children with relapsed ALL with mitoxantrone based protocol- A prospective observational study	Dr. Nirmalya Moulik	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2020	15.61	5 Years
Evaluation of distress in survivors of cervical cancer.	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2021	6.25	2 Years
Clinicopathological features of Cervical adenocarcinomas: A study for a tertiary cancer referral center from 2010-2015.	Dr. Bharat Rekhi	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2021	2.60	2 Years
PIK3CA mutation prevalence and clinicopathological association in breast carcinomas	Dr. Sangeeta Desai	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2021	17.53	2 Years
CDKN2A deletion in IDH-mutant diffuse astrocytic tumors	Dr. Sridhar Epari	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2021	10.73	2 Years
Effect of topical coconut oil application versus standard supportive care on xerostomia related quality of life among patients with radiation induced xerostomia in H& N cancer patients in tertiary care cancer center- A randomized control trial	Mrs. Meera Achrekar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2021	0.6	1 Years 10 Days
Enhanced Recovery Pathway in Head and Neck Cancer Surgery	Dr. Vandana Agarwal	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2021	7.41	2 Years
Evaluation of PDL1 Antibody SP142 in Triple Negative Breast Cancer (TNBC).	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2022	8.18	1 Years
National Quality Assurance (NQA) program in Biochemistry for Electrophoresis, Immunofixation and Tumor markers in centers of the National Cancer Grid	Dr. Kinjalka Ghosh	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2021	60.52	3 Years
PROspective Study on the use of gEriatric assessment Tools for validation of 1-year mortality in breast cancer patients 65 years and older (PROTECT)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2021	10.20	3 Years
Prostate Health Index (PHI) - Is it a Master Key for Diagnosis of Prostate Cancer?	Dr. Kinjalka Ghosh	Beckman Coulter Pvt. Ltd.	Non-Government	Medical & Health Science	2021	23.00	2 Years

Compilation of data as received from Dean-Academic of *various* **Dr. P. C. Selvin** / **Prof. P. C. Selvin**

कुलसचिव / REGISTRAR / HBI
Dr. P. C. Selvin
HOMI BHABHA NATIONAL INSTITUTE
 शिक्षण विद्यालय परिसर, आंध्रकरी नगर, मुंबई - ४०० ०९४
 Training School Complex, Anandkri Nagar, Mumbai - 400 094

Assessment of the Breast Cosmesis using Deep neural networks: an exploratory study (ABCD)	Dr. Tabassum Wadasadawala	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	10.20	3 Years
To Study the Challenges in implementing the government funded health schemes for the treatment of cancer patients in Tata Memorial Centre, Mumbai.	Dr. Atul Budukh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	9.05	1 Years 6 Months
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	Dr. Badira Parambil	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	53.53	10 Years
Pilot testing of Hindi and Marathi translations of the European Organization for the Research and Treatment of Cancer (EORTC) module, assessing quality of life in patients with primary vulva cancer (EORTC QLQ VU34).	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	0.1	1 Years 6 Months
Clinicopathological Review of Breast Carcinoma with Lobular Features	Dr. Sangeeta Desai	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	2.71	1 Years
Ambispective registry of oligometastatic and oligorecurrent head and neck cancer patients treated at Tata Memorial Hospital.	Dr. Monali Swain	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	23.23	5 Years
Retrospective Evaluation of Immunohistochemical 'Histone modifying' epigenetic underpinnings of Breast carcinomas	Dr. Tanuja Shet	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	13.74	1 Years
Effect of Terlipressin in Patients Undergoing Major Hepatectomies for Liver Cancers: A Prospective Randomized Controlled Phase-III Trial (TerliHep Trial)	Dr. Sohan Solanki	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	25.69	4 Years
Clinical outcomes and quality of life in patients with locally advanced vulvovaginal cancers: Ambispective registration study.	Dr. Supriya Chopra	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	5.99	5 Years
Correlation of O6 -Methyl(Alkyl) Guanine-DNA Methyl(Alkyl) Transferase (MGMT/AGAT) Gene Polymorphisms with Hematological Toxicity of Temozolomide in Adult Diffuse Glioma (MAGENTA) - A Case-Control study	Dr. Tejpal Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2022	5.29	2 Years
Developing a 3D-printed Humanoid Phantom for Breast Cancer Radiotherapy Dosimetry and Quality Assurance	Dr. Rajiv Sarin	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2021	0.36	2 Years
Three field radical esophagectomy versus two field esophagectomy a prospective randomized controlled trial	Dr. C. S. Pramesh	TMC-Corporate Research fund	Non-Government	Medical & Health Sciences	2004	37.64	18 Years

Compilation of data as received from Dean-Academic of various CI's/CC of HBNI.


 प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094

A prospective randomized trial of neo-adjuvant chemotherapy and surgery versus concurrent chemoradiation therapy in patients with stage IB2-IIB squamous carcinoma of the uterine cervix	Dr. Sudeep Gupta	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2003	63.16	19 Years 5 Months 20 Days
Phase III trial of surgery followed by conventional radiotherapy (5 fractions/ week) vs concurrent chemoradiotherapy vs accelerated radiotherapy (6 Fractions/week) in high risk, locally advanced stage III & IVA, resectable, squamous cell carcinoma of oral cavity	Dr. Sarbani Ghosh Laskar	TMC-Corporate Research fund	Non-Government	Medical & Health Science	2005	38.99	17 Years 5 Months 15 Days

Compilation of data as received from Dean-Academic of various CI's/oc of HBNI.

प्रो. पी. सी. सेल्विन / Prof. P. C. Selvin
 कुलसचिव / REGISTRAR
 होमी भाभा राष्ट्रीय संस्थान
 HOMI BHABHA NATIONAL INSTITUTE
 प्रशिक्षण विद्यालय परिसर, अणुशक्ती नगर, मुंबई - ४०० ०९४
 Training School Complex, Anushakti Nagar, Mumbai - 400 094